|
|
Development of brain-penetrant MNK inhibitors
| Third-party funded project |
| Project title |
Development of brain-penetrant MNK inhibitors |
| Principal Investigator(s) |
Genç, Özgür
Lill, Markus A.
Scheiffele, Peter
|
| Organisation / Research unit |
Departement Pharmazeutische Wissenschaften / Computational Pharmacy (Lill),
Departement Biozentrum / Cell Biology (Scheiffele) |
| Department |
Departement Biozentrum |
| Project start |
01.03.2023 |
| Probable end |
30.08.2024 |
| Status |
Active |
| Abstract |
MAP-kinase interacting kinases (MNKs) are a novel target for the treatment of autism spectrum disorders. We aim to develop a brain-penetrant, small molecule inhibitor that selectively targets MNKs and alleviates the core symptoms of autism. |
| Financed by |
Innovation Promotion Agency CTI
|
| |
|
|
MCSS v5.8 PRO. 0.424 sec, queries - 0.000 sec
©Universität Basel | Impressum
|  |
|
11/05/2024
Research Database / FORSCHUNGSDATENBANK
|
